HMC · NYSE
| FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | $11.84T | $9.88T | $7.95T | $8.94T | $8.58T | $10.01T | $12.00T |
| Cost of Revenue | $8.76T | $7.35T | $5.92T | $6.50T | $6.41T | $7.42T | $8.54T |
| Research & Development | $634.13B | $560.27B | $519.82B | $487.59B | $463.35B | $563.20B | $587.96B |
| Selling, General & Administrative | $1.70T | $1.43T | $1.28T | $1.38T | $1.34T | $1.84T | $1.92T |
| Operating Expenses | $11.09T | $9.33T | $7.72T | $8.37T | $8.22T | $9.82T | $11.05T |
| Operating Income | $750.28B | $544.81B | $231.36B | $569.77B | $363.77B | $189.64B | $953.11B |
| Interest Expense | $12.70B | $12.16B | $10.38B | $8.47B | $12.55B | $22.54B | $16.62B |
| Other Income / (Expense) | -$21.34B | -$55.92B | $26.04B | $60.77B | -$27.58B | -$27.91B | -$57.27B |
| Income Before Taxes | $728.94B | $488.89B | $257.40B | $630.55B | $336.20B | $161.73B | $895.84B |
| Provision for Income Taxes | $252.66B | $178.98B | $135.74B | — | $146.87B | $109.83B | $387.44B |
| Net Income | $574.11B | $367.15B | $211.48B | $534.09B | $268.40B | $137.00B | $600.04B |
| Basic EPS | $318.54 | $203.71 | $117.34 | $295.67 | $147.91 | $75.50 | $330.54 |
| Basic Shares Outstanding | 1.80B | 1.80B | 1.80B | 1.81B | 1.81B | 1.81B | — |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Mar 2027 | $1.65 | $1.28 | $2.37 | 3 | ↑1 ↓0 |
| Mar 2028 | $3.14 | $2.66 | $3.65 | 3 | ↑0 ↓0 |
| Mar 2029 | $3.23 | $2.89 | $3.57 | 2 | ↑0 ↓0 |
| Mar 2030 | $2.97 | $2.97 | $2.97 | 1 | ↑0 ↓0 |